Marinus started at buy by Baird

Baird initiates coverage on Marinus Pharmaceuticals (NASDAQ: MRNS) with an Outperform rating and a price target of $15.00.

Analyst Brian Skorney commented, “We think upcoming Phase 2 data for ganaxolone in post-partum depression will lay out a path for an IV and oral option in this unmet medical need. Sharing almost identical characteristics to Sage Therapeutics’s (not covered) brexanolone and SAGE-217, we think clinical results, expected later this year, should also look similar, leading the company to a much higher valuation.”

https://bit.ly/2GMTtlC